The DOI matches its Crossref record.
Platelet Transfusion Therapy
Abstract
In the past, patients with chronic thrombocytopenia died of hemorrhage with distressingly predictable frequency. The increased use of platelet transfusions during the past 15 years has prevented most such deaths. Furthermore, this therapy has made it possible to treat patients who have otherwise fatal disorders with drugs that temporarily suppress platelet production. With this great benefit, however, have come complex problems. Transfused platelets can transmit fatal diseases and can elicit an immune response in recipients, so that further transfusions are no longer effective. Although platelet therapy has contributed greatly to the treatment of patients with many diseases (eg, acute leukemia and aplastic anemia), serious questions have emerged regarding its use in patients undergoing cardiac surgery and in other circumstances. The prophylactic administration of platelets is also controversial, and there is uncertainty as to the platelet levels that predispose thrombocytopenic patients to hemorrhage and as to the effectiveness of modalities other than platelets in the prevention of bleeding. The relative merits of the various methods for obtaining and storing platelets remain unclear. The advantages and disadvantages of the use of platelets obtained from multiple and single donors require evaluation. To resolve these issues, the National Heart, Lung, and Blood Institute, the Center for Drugs and Biologics of the Food and Drug Administration, and the Office of Medical Applications of Research convened a Consensus Development Conference on Platelet Transfusion Therapy Oct 6 to 8, 1986. At a 1 1/2-day series of presentations by experts in the field, a consensus panel drawn from the medical professions, blood banking organizations, and the general public considered the evidence. The panel agreed on answers to the following key questions: What are the appropriate indications for platelet transfusion? What products are available, and what are their relative merits? What are the risks associated with platelet transfusion? What are the most important directions for future research?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell Concentrates
Hiippala, S. T., Myllyla, G. J., & Vahtera, E. M. (1995) · Anesthesia & Analgesia · doi:10.1097/00000539-199508000-00026 · Cited by 703
Prudent Strategies for Elective Red Blood Cell Transfusion
Welch, H. G., Meehan, K. R., & Goodnough, L. T. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-5-393 · Cited by 353
McVay, P. A., & Toy, P. T. C. Y. (1991) · Transfusion · doi:10.1046/j.1537-2995.1991.31291142949.x · Cited by 269
Role of fibrinogen in trauma-induced coagulopathy
Fries, D., & Martini, W. Z. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq161 · Cited by 254
Prediction and management of bleeding in cardiac surgery
DESPOTIS, G., AVIDAN, M., & EBY, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03412.x · Cited by 99
Metadata
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1987-04-03
- Volume
- 257
- Issue
- 13
- Pages
- 1777
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2409262121
- Cited by
- 193
- References
- 0
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet Transfusion Therapy. https://app.cochat.ai/papers/10.1001/jama.1987.03390130095036
- The paper
- Platelet Transfusion Therapy. (1987). JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1987.03390130095036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.